drugset
drugset / Trial / NCT05607342

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

NCT05607342 ↗

Phase 0 Terminated 1 enrolled University of Kansas Medical Center
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.

Timeline

Start
2023-01-03
Primary completion
2023-09-22
Completion
2023-11-06

Outcome

Outcome not reported

Stopped: “Development of the drug program has been discontinued”

Drugs

EvaluationDrugModalityDoseRoute
Subject Osanetant Small molecule 200 mg Oral

Indications

prostate adenocarcinoma